Need and Potential of Antimicrobial Stewardship in Community Hospitals

被引:87
作者
Septimus, Edward J. [1 ]
Owens, Robert C., Jr. [2 ]
机构
[1] HCA Healthcare Syst, Dept Internal Med, Texas A&M Hlth Sci Ctr, Houston, TX USA
[2] Maine Med Ctr, Antimicrobial Stewardship Program, Dept Pharm Serv, Div Infect Dis, Portland, ME 04102 USA
关键词
RESISTANT STAPHYLOCOCCUS-AUREUS; INFECTIOUS-DISEASES-SOCIETY; HEALTH-CARE-EPIDEMIOLOGY; CLOSTRIDIUM-DIFFICILE; ECONOMIC OUTCOMES; ACQUIRED PNEUMONIA; OF-AMERICA; NO ESKAPE; BAD BUGS; PROGRAM;
D O I
10.1093/cid/cir363
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Preventing, reducing, and controlling the emergence of antimicrobial-resistant organisms is a major public health challenge requiring the participation of the entire medical community and public health agencies. Antimicrobial stewardship programs (ASPs) have the potential to integrate the many and sometimes disparate individuals and organizations that rely on antimicrobial agents in an effort to better control antimicrobial prescribing, possibly minimizing the emergence of resistant organisms. Developing and implementing ASPs can be a major challenge for community-based hospitals. In addition to specific and localized patterns of resistance-a consideration for every hospital-community hospitals must develop strategies that appropriately conform to their size, staffing, personnel, and infrastructure. This article reviews the ASP strategies and resources currently available to community hospitals for improving if, when, and how antimicrobial agents are prescribed and delivered.
引用
收藏
页码:S8 / S14
页数:7
相关论文
共 32 条
  • [1] [Anonymous], 2010, Am J Health Syst Pharm, V67, P575, DOI 10.2146/sp100001
  • [2] Clinical and economic outcomes of pharmacist-managed antimicrobial prophylaxis in surgical patients
    Bond, C. A.
    Raehl, Cynthia L.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (18) : 1935 - 1942
  • [3] Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy
    Bond, CA
    Raehl, CL
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (15) : 1596 - 1605
  • [4] Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
    Boucher, Helen W.
    Talbot, George H.
    Bradley, John S.
    Edwards, John E., Jr.
    Gilbert, David
    Rice, Louis B.
    Scheld, Michael
    Spellberg, Brad
    Bartlett, John
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) : 1 - 12
  • [5] Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections
    Calbo, E
    Garau, J
    [J]. RESPIRATION, 2005, 72 (06) : 561 - 571
  • [6] Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK
    Delaney, J. A. Chris
    Dial, Sandra
    Barkun, Alan
    Suissa, Samy
    [J]. EMERGING INFECTIOUS DISEASES, 2007, 13 (05) : 761 - 763
  • [7] Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship
    Dellit, Timothy H.
    Owens, Robert C.
    McGowan, John E., Jr.
    Gerding, Dale N.
    Weinstein, Robert A.
    Burke, John P.
    Huskins, W. Charles
    Paterson, David L.
    Fishman, Neil O.
    Carpenter, Christopher F.
    Brennan, P. J.
    Billeter, Marianne
    Hooton, Thomas M.
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (02) : 159 - 177
  • [8] High-dose, short-course Levofloxacin for community-acquired pneumonia: A new treatment paradigm
    Dunbar, LM
    Wunderink, RG
    Habib, MP
    Smith, LG
    Tennenberg, AM
    Khashab, MM
    Wiesinger, BA
    Xiang, JX
    Zadeikis, N
    Kahn, JB
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (06) : 752 - 760
  • [9] *EUR CDCP, ECDC EMEA JOINT TECH
  • [10] FORD W, NEW STRATEGIES ANTIM